Greenland Mines (GRML) vs ImageneBio (IMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImageneBio (IMA) has outperformed Greenland Mines (GRML) over the past year, losing 44.9% versus a loss of 87.1%. ImageneBio is the larger company by market cap ($48.8 million vs $44.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRML | IMA |
|---|---|---|
| Share price | $2.99 | $3.92 |
| Market cap | $44.31M | $48.83M |
| 1-day change | +2.75% | 0.00% |
| YTD return | -79.31% | -43.19% |
| 1-year return | -87.08% | -44.87% |
| 5-year return | — | -97.86% |
| EPS (TTM) | $-9.74 | $-2.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $800.00K |
| Revenue growth (YoY) | — | -77.14% |
| Net income (latest FY) | $-10.55M | $-45.35M |
| Operating margin | — | -6056.38% |
| Net margin | — | -5668.63% |
| 52-week high | $37.00 | $7.60 |
| 52-week low | $2.75 | $3.00 |
| Distance from 52-week high | -91.92% | -48.42% |
| Analyst consensus | none | none |
| Avg. price target upside | +3578.93% | +359.18% |
| Average volume | 8.93M | 15.86K |
| Shares outstanding | 14.82M | 12.46M |
| Employees | 5 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMA has outperformed GRML by 42.2 percentage points over the past year.
About Greenland Mines
GRML stock →Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About ImageneBio
IMA stock →ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
GRML vs IMA FAQ
Which is bigger, Greenland Mines or ImageneBio?
ImageneBio (IMA) is larger, with a market capitalization of $48.83M compared with $44.31M for Greenland Mines (GRML).
Which stock has performed better over the past year, GRML or IMA?
IMA returned -44.87% over the past 12 months, compared with -87.08% for GRML (price return, excluding dividends). Past performance does not predict future results.
Are Greenland Mines and ImageneBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.